[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Amydis Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":86},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,62],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100555585","phase-2-a-study-of-amdx-2011p-in-participants-with-alzheimers-disease-100555585",false,"NCT06514001","A Study of AMDX-2011P in Participants With Alzheimer's Disease","A Phase 2, Open Label, Study of AMDX-2011P as a Retinal Tracer in Participants With Alzheimer's Disease","Inclusion Criteria:\n\n1. Confirmed diagnosis of Alzheimer's Disease (AD) with documented positive amyloid beta signal via positron emission tomography (PET) brain scan\n2. Must be willing to consent to genotyping for apolipoprotein E (APOE)\n3. Ability to fixate and undergo retinal imaging of both eyes\n\nExclusion Criteria:\n\n1. Presence of any underlying physical or psychological medical condition that, in the opinion of the investigator, would make it unlikely that the participant will complete the study per protocol\n2. Diagnosis of glaucoma, or suspect of having glaucoma in either eye as determined by an ophthalmologist as a clinical investigator, based on results from the eye examination, visual field, and\u002For optical coherence tomography (OCT) results\n3. Diagnosis of intermediate dry, wet\u002Fneovascular, or geographic atrophy forms of age-related macular degeneration (AMD) in either eye, OR as determined by an ophthalmologist as a clinical investigator, based on results from the eye examination and\u002For optical coherence tomography (OCT) results\n4. Clinically significant laboratory abnormalities as assessed by the investigator\n5. Prolonged QTcF (corrected QT interval by Fridericia method) (\\>450 ms for males and \\>470 ms for females), cardiac arrhythmia, or any clinically significant abnormality in the resting electrocardiogram (ECG), as judged by the investigator.","ALL","18 Years",{"count":19,"type":20},25,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).",[26],"Alzheimer Disease",[28],"AD","RECRUITING","2026-02-11",{"date":32,"type":33},"2026-02-13","ACTUAL",{"date":35,"type":33},"2025-03-07",{"date":37,"type":20},"2026-10",{"name":39,"class":40},"Amydis Inc.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":56,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":41},"100493758","phase-2-a-study-of-amdx-2011p-in-participants-with-caa-100493758","NCT05709314","A Study of AMDX-2011P in Participants With CAA","A Phase 2, Open-Label Study of AMDX-2011P as a Retinal Tracer in Participants With Cerebral Amyloid Angiopathy (CAA)","Inclusion Criteria:\n\n1. Diagnosis of hereditary CAA or probable and definite symptomatic or asymptomatic sporadic CAA diagnosed through genetic testing or according to the modified Boston neuroradiological criteria, who had undergone at least one brain magnetic resonance imaging (MRI)prior to entry into study.\n2. Abnormality consistent with CAA on historical MRI.\n3. In general good health\n\nExclusion Criteria:\n\n1. Presence of any underlying physical or psychological medical condition that, in the opinion of the investigator, would make it unlikely that the participant will complete the study per protocol.\n2. Clinically significant laboratory abnormalities assessed by the investigator.\n3. Active malignancy and\u002For history of malignancy in the past 5 years, with the exception of completely excised non-melanoma skin cancer or low-grade cervical intraepithelial neoplasia.\n4. Prolonged QTcF (\\>450 ms for males and \\>470 ms for females),cardiac arrhythmia, or any clinically significant abnormality in the resting ECG, as judged by the investigator.",{"count":19,"type":20},[23],"The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).",[53],"Cerebral Amyloid Angiopathy",[55],"CAA",{"date":32,"type":33},{"date":58,"type":33},"2024-07-09",{"date":60,"type":20},"2026-12",{"name":39,"class":40},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":72,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":5},"100533225","phase-2-a-study-of-amdx-2011p-in-participants-with-primary-open-angle-glaucoma-100533225","NCT06223048","A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma","A Phase 2, Randomized, Open Label Study of AMDX-2011P as a Retinal Tracer in Participants With Primary Open Angle Glaucoma","Inclusion Criteria:\n\n1. Diagnosis of primary open angle glaucoma in both eyes\n2. Able to fixate\n3. Glaucomatous optic nerve damage in both eyes, as determined by an investigator as part of an eye exam\n\nExclusion Criteria:\n\n1. Participants unable to read or write\n2. Ocular media is not sufficiently clear to obtain acceptable quality images\n3. Participants with presence of any ocular pathology other than glaucoma in the study eye (cataracts are acceptable)","22 Years",{"count":71,"type":20},50,[23],"The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG).",[75],"Primary Open Angle Glaucoma",[77],"POAG","2024-07-29",{"date":80,"type":33},"2024-07-30",{"date":82,"type":33},"2023-12-07",{"date":84,"type":20},"2025-02",{"name":39,"class":40},""]